ArticleFrontiers in oncology2025
The influence of extraprostatic extension grade on the detection of pelvic lymph node metastasis in prostate cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study was conducted to evaluate any association between extraprostatic extension (EPE) grade with the risk of pelvic lymph node metastasis (PLNM) of prostate cancer (PCa). Methods: Magnetic resonance imaging data, as well as clinical and pathological data were collected for 317 patients undergoing radical prostatectomy (RP) along with pelvic lymph node dissection (PLND) at Ningbo Yinzhou No. 2 Hospital from January 2019 to January 2024. The collected magnetic resonance images were scored employing the EPE grade. The factors associated with PLNM were analyzed through Chi-square test and independent sample T-test. Independent risk factors associated with PLNM were identified through Multivariate analyses. The area under the curve (AUC) was calculated and the diagnostic performance of the model was assessed by analyzing the receiver operating characteristic (ROC) curve. The clinical net benefit of EPE grade, biopsy positive rate, and the combined model were examined using clinical decision curves. Results: Among 317 patients, 33had PLNM. Multifactor analysis demonstrated EPE grade and biopsy positive rate as independent risk factors for PLNM of PCa. The AUC of EPE grade and biopsy positive rate was, respectively, 0.879 and 0.877, and the diagnostic efficiency of PLNM between the two was not statistically significant (P > 0.05). However, when the two approaches were combined, the diagnostic efficiency improved significantly, and the AUC increased to 0.921 (P < 0.05). The analysis of the clinical decision curve revealed a significantly higher clinical net benefit of the combined model than that of the EPE grade and biopsy positive rate. Conclusions: The EPE grade and biopsy positive rate exhibit an independent correlation with PLNM of PCa. In addition, the combination of the two can significantly enhance the accuracy of predicting PLNM of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.